Purolite Announced about the Introduction of its Praesto Agarose-Based Chromatography Resins into the Commercial Manufacturing of Biotherapeutics
Purolite Ltd. has announced that its Praesto agarose-based chromatography resin range is being utilized for the commercial manufacturing of FDA-approved biotherapeutics. Usually, these resins by Praesto are used for the purification of modern medicines targeting the treatment of cancer, rheumatoid arthritis, dementia, and diabetes.
Chromatography resins are resins that are used for the separation or purification purpose of proteins or any other bio-molecular particles in pharmaceutical, environmental analysis, food manufacturing, and biotechnology. These resins are categorized into three types, viz., synthetic, natural and inorganic media. Natural and synthetic resins are favored over inorganic media.
Stratview Research published a report lately in which it has stated that the Chromatography Resin Market is likely to witness an impressive CAGR of 9.2% during the forecast period. The increasing demand for chromatography resins in the pharmaceutical & biotechnology, food & beverage, and water & environmental analysis is driving the market globally.
Chris Major, Global Sales and Marketing Director for the Agarose division of Purolite Life Sciences, comments, “This is a major milestone for Purolite Life Sciences, and we are truly proud that our resin technology will be used by customers in FDA-approved commercial manufacturing processes. The adoption of our Praesto product range is a testament to our technology leadership, differentiating us from competitors with ‘best in class’ performance, shorter lead times, and a strong commitment to the security of supply. Purolite has invested over $150 million into a global expansion program in recent years, as a continued commitment to resin innovation, including doubling the production capacity of our unique, uniform-bead jetting technology. We look forward to continuing to meet our customer’s growing demand for this high-performance resin.”
The latest investment of Purolite to increase production capacity of its proprietary, uniform-particle-size manufacturing process comes just after a year of opening one of the largest agarose-based resin manufacturing facilities in the world. This UK-based facility boasts a 100,000L capacity that is equal to about 30% of the annual global demand.